Logo - springer
Slogan - springer

Springer Healthcare | Diabetes Therapy (Editorial Board)

Diabetes Therapy

Diabetes Therapy

Research, treatment and education of diabetes and related disorders

Co-Editors-in-Chief: Marc Evans
Co-Editor-in-Chief: Fernando Ovalle

ISSN: 1869-6961 (electronic version)

Journal no. 13300

Editors-in-Chief

Europe
Marc Evans, University Hospital Llandough, Llandough, UK

USA
Fernando Ovalle, University of Alabama at Birmingham, Birmingham, AL, USA

Editorial Board

Carlos A. Aguilar Salinas, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico
Henninng Beck-Nielsen, University of Copenhagen, Copenhagen, Denmark
Bernard Charbonnel, University of Nantes, Nantes, France
Robert Henry, University of California, San Diego, and Center for Metabolic Research, San Diego, CA, USA
Michael Horowitz, University of Adelaide, Adelaide, Australia
Takashi Kadowaki, University of Tokyo, Tokyo, Japan
Sanjay Kalra, Bharti Hospotal and BRIDE, Karnal, India
Rayaz Malik, University of Manchester and Manchester Royal Infirmary, Manchester, UK
Vincent Woo, University of Manitoba, Winnipeg, Canada

Advisory Board

Caroline Abbott, Neera Agarwal, Rupa Ahluwalia, Uazman Alam, Mohammed Ali, Ioannis Bassuka, Ananda Basu, Peter Bennett, Huriya Beyan, Donald Bowden, Arrigo Cicero, John Colwell, Walmir Coutinho, Sylvie Dejager, Baltzis Dimitrios, Deep Dutta, Steven Elbein, Jackie Elliott, Martha Funnell, Ben Gerber, Kathleen Gillespie, Antonio González Chávez, Alfredo Halpern, Martin Haluzik, Stanley Hsia, Michael Ip, Sanjay Kalra, Amy Kennedy, Mohammad Khamseh, Guido Lastra-Gonzalez, Eldon Lehmann, Cathy Lloyd, Viswanathan Mohan, Stein Neilsen, Susana Patton, Valentina Petkova, Mark Peyrot, Gretchen Piatt, Hermione Price, Adam Rose, Ellen Schneiderman, Antonio Secchi, Heena Sheth, Solomon Tesfaye,  Jeff Unger, Zhongya Wang, Nancy West, Daniel Witte

 

Articles

For authors and editors

  • Aims and Scope

    Aims and Scope

    Close

    Diabetes Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality preclinical, clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of diabetes therapies. Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also encouraged.

    The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports, and short communications. The journal appeals to a global audience and receives submissions from all over the world.

    Moving forward from traditional publishing, Diabetes Therapy offers a range of additional enhanced features designed to increase visibility, readership, and the educational value of the content. Each paper is accompanied by a bulleted Summary slide, giving a time-efficient overview of the content to a wide readership. Articles also have the option to include slide sets, videos, animations, and/or interactive learning resources. All enhanced features are open access and are peer reviewed to the same high standard as the article itself.

    Diabetes Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/2.5.

    Upon acceptance of your article for publication, you will be required to pay the article processing charge of £210/€250/$320 per printed page. This will enable you to keep the copyright; you are simply assigning the exclusive right to any commercial use of the article to Springer. Your article will be immediately and permanently available with open access.

    For more information about the journal, please contact hayley.wood@springer.com or see the News page for the latest journal offers.

  • Submit Online
  • Instructions for authors (pdf, 188 kB)
  • Author Disclosure form (pdf, 131 kB)
  • Compliance with Ethical Policies
  • Author Academy: Training for Authors
  • Copyright information

    Copyright information

    Close

    Copyright Information

    Open Access Diabetes Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0

    Journal ownership: Springer Healthcare

    Copyright of articles: © The Author(s)

Alerts for this journal

 

Get the table of contents of every new issue published in Diabetes Therapy.